Background. Controlled clinical trials have reported treatment effects evaluated with serial imaging in coronary and femoral but not cervical arteries. The Cholesterol Lowering Atherosclerosis Study, a coronary, cervical, and femoral angiographic trial of colestipol plus niacin, included a pilot study of standardized carotid ultrasound imaging.
here are two general strategies for clinical trials testing the efficacy of treatments for atherosclerosis: 1) study of symptoms, morbidity, or mortality and 2) measurement of the rate of atherosclerotic lesion change with serial vessel imaging. Coronary arterial imaging has been used for evaluation of several diets,12 a variety of hypolipemic and calcium channelblocking drugs,3-7 and partial ileal bypass surgery for blood cholesterol lowering.8 Serial femoral angiography has been used in two completed trials,9"10 and preliminary femoral results have been reported for one study in progress.1' The natural history of carotid bifurcation lesions has been studied with serial intravenous digital tDr Crawford died October 1992. tDr Blankenhorn died May 9, 1993. The Cholesterol Lowering Atherosclerosis Study (CLAS) was a randomized, placebo-controlled, angiographic trial testing colestipol-niacin plus diet therapy in nonsmoking men with previous coronary bypass surgery.'4 Target vessels (coronary, cervical, and femoral) were chosen to provide as complete a survey of See p 319 atherosclerosis as possible, consistent with patient safety, with an emphasis on full coronary arteriography for panel and computer image-processed analyses. We have previously reported clear treatment benefit on coronary arteries at both 2 and 4 years using a coronary end point measure based on panels of human readers. 6 Computerized femoral angiographic results at 2 years have indicated therapy benefits that are significant but less consistent than coronary angiography. 10 CLAS also included a pilot study of carotid B-mode ultrasound imaging methodology. We now report clear evidence of benefit from colestipol-niacin therapy in carotid B-mode images from 78 subjects after 2 and 4 years of treatment. We examine the relation of carotid 
Methods

Subjects and Study Regimen
The CLAS design has been described in detail.14 In brief, 188 nonsmoking men aged 40 to 59 years with progressive atherosclerosis and previous coronary bypass surgery were randomized to colestipol plus niacin (D) and diet or placebo (P) and diet (see Table 1 ). Twenty-nine percent of the 188 never smoked, and 71% were ex-smokers for more than 6 months. Average age at entry was 54.2±0.5 (SEM) years; average blood pressure was 124±2/81 ± 1 mm Hg. Entry fasting blood cholesterol levels averaged 6.31 mmol/L (245 mg/dL).
Levels of physical activity were moderate as judged from questionnaires, records of caloric intake, and serial measurement of body weight.
The 4-year average drug intake was 30.1 g per day colestipol, 4.2 g per day niacin. Drug and placebo groups received diet intervention with different diet composition to enhance the difference in blood cholesterol responses between the two groups. The target diet prescribed for the placebo group included a daily intake of <250 mg cholesterol and provided 26% of energy as fat calories, 10% as polyunsaturated fat, and 5% as saturated fat. The target diet prescribed for the drug group included <125 mg cholesterol per day and provided 22% of energy as fat calories, 10% as polyunsaturated fat, and 4% as saturated fat.
Blood lipid, lipoprotein cholesterol, and apolipoprotein determinations were performed on samples obtained after an overnight fast with methods previously described.14 Cholesterol, triglycerides, and cholesterol from the high density lipoprotein (HDL-C), isolated by precipitation of the low density species, were analyzed by the Lipid Research Clinic's methodology15 and were standardized against reference materials supplied by the National Center for Disease Control. Low density lipoprotein cholesterol (LDL-C) was calculated as follows: LDL-C equals cholesterol minus HDL-C minus triglyceride divided by 5 A similar process was used to determine the coordinates of the media/adventitia echo. Vessel diameter in the distal 10 mm of the common carotid artery was determined as the average at 120 points of the distance between the near-wall intima/lumen echo and the farwall lumen/intima echo. Intima-media wall thickness was determined in the same area of the common carotid artery as the average difference at 120 points between intima/lumen and media/adventitia boundary echoes. Diameter and intima-media thickness measurements were stored in an ASCII data base.
Measurement variability. Intra-operator and interoperator variability in computer measurement of intimamedia thickness was assessed using ultrasound tapes from 20 subjects. Three operators measured far-wall intima-media thickness; one operator repeated the measure three times, one operator repeated the measure two times, and the third operator performed the measurements one time only. By ANOVA, there was significant variability between subjects (P<.0001) and no significant differences between operators or between repeated measurements by the same operator. Intraoperator and interoperator intraclass correlations both were .97. Coefficients of variation within readers was 3.0% and between readers was 3.1%.
Comparison of computer measurements with visual scores. Highest visual grades recorded in the carotid bulb and internal carotid arteries were tabulated and correlated with computer-measured intima-media thickness. Sixty-seven among 78 subjects had abnormal visual scores (7.5% scored 1.5; 41.8%, 2.0; 11.9%, 2.5; 25.4%, 3 Cervical angiograms were digitized with a Joyce Loebl Scandig 3 rotating drum digitizer. In this instrument, a tungsten halogen lamp is mounted opposite a photo diode on an optical carriage that moves along the axis of the transparent rotating drum. All picture elements are scanned with the same light source and sensor combination. Density linearity of this system was plus/minus three parts in 256 from a best-fit straight line. Density repeatability was plus/minus one part in 256. Fifty-micron digital sampling was used for this experiment.
To find the edges of a vessel, the computer operator first identified the approximate vessel midline with a cursor. The computer algorithm then searched perpendicular to this midline to find points of maximum intensity gradient that were identified as vessel edges. The search was restricted to a window of pixel values centered on the prior detected edge point. For each detected edge point on one lumen wall, the nearest edge point on the opposite wall was located, and the midpoint between the pair was identified. The series of lumen midpoints was smoothed and used to represent the computer-derived vessel midline. The computerderived midline was then used to retrack the vessel edges, and a new midline was computed. This "twopass" procedure was used to minimize the effect of the selection of an original midline by the technician.
For each edge, an edge profile was defined by the distance between the detected edge points and the midline. Roughness for each edge was next defined as the root-mean-square difference between the edge profile and a minimum least-square straight line fit to the proffle. 
Statistical Analysis
To establish baseline comparability, the two ultrasound subgroups (n=78, n=46) were compared with CLAS subjects not having ultrasound on baseline lipids, apolipoproteins, and other clinical variables using a two-sample t test. Percent differences in these variables at baseline were also computed. Baseline levels were also compared in drug and placebo subjects within each of these ultrasound groups. Baseline variables were computed as the average of all prerandomization measures. On-trial variables were computed as the average of all on-trial determinations, weighted by the scheduled interval between clinic visits (either 1 or 2 months). Changes from baseline in lipid and other clinical variables were tested within each treatment group using the paired t test and between treatment groups using the two-sample t test. Treatment group comparisons of carotid intima-media thickness at baseline, on-trial, and change (on-trial minus baseline measure) were also performed using two-sample t tests.
The association between carotid intima-media thick- Table 2 indicates significant effects within and between treatment groups in ultrasound measurements of far-wall thickness at 2 and 4 years in the 78 CLAS subjects. The average months (±SD) from baseline to 2-year ultrasound was 24±5 in the drug group and 26±6 in the placebo group (NS) and from baseline to 4-year ultrasound was 40±11 in the drug group and 38± 13 in the placebo group (NS). At 2 years (P=.0001) and 4 years (P=.0004), thickness was significantly diminished in the drug group and increased (P=.0008, 2 years; P=.0002, 4 years) in the placebo group. Change in wall thickness differed significantly in drug and placebo groups at 2 and 4 years (both P<.0001). There were no significant changes in carotid diameter within or between either group. Table 3 presents a detailed comparison of baseline and on-trial lipid, lipoprotein, and clinical measurements in the two treatment groups of the subset of 46 subjects. There were no significant baseline differences between treatment groups. Table 3 also compares the subset of 46 with all other randomized CLAS subjects. There were no significant baseline differences except for Apolipoprotein (Apo) A-I, which was significantly lower in the subset of 46 than in all other CLAS subjects (P<.05). Treatment with colestipol-niacin significantly reduced on-trial total cholesterol and LDL-C, Apo B, and Apo C-III (heparin precipitate) and increased HDL-C, Apo A-I, Apo C-III (heparin supernate), and 127 (17) 120 (14) 144 (17) 123 (13) 133 (31) 120 (31) 86 (19) 119 (23) 12 (3) 11 ( (7) 89 (7) 122 (15) 118 (13) 118 (13) 119 (11) 27 (3) 26 (2) 26 ( (8) 120 (14) 123 (12) 119 (12) 120 (11) 26 (3) 26 (3) 27 ( the Apo C-III ratio (supernate/precipitate). Response to treatment in the 46 subjects did not differ from that of all other randomized subjects. far-wall intima-media thickness did not differ significantly in the two groups at baseline but was significantly greater in the placebo group at 4 years (P<.03). Thus, a significant difference in group means, the most common end point adopted for clinical trials, is demonstrated at 4 years, with 22 and 24 subjects per treatment group. The subset of 46 subjects also demonstrates significant increase in wall thickness at 2 years (P=.007) and 4 years (P=.002) with placebo treatment. Drug treatment results in significant reduction of wall thickness at 2 (P=.001) and 4 years (P=.001) ( Table 4) . At 2 and 4 years, the change in intima-media thickness from baseline was significantly different between treatment groups (P<.0001). Ultrasound-measured carotid diameter and angiographic edge roughness showed no significant changes over time.
In the subset of 46 subjects with cervical angiographic views with matching ultrasound images, there was significant correlation between far-wall thickness and average coronary stenosis at baseline (r=.34, P<.05) and carotid angiographic edge roughness at 2 years (r=.31, P<.05).
These correlations were not significant at 4 years. Table 5 summarizes the univariate correlations between change in ultrasound-measured wall thickness and on-trial lipid risk factors. At 2 and 4 years after randomization, reduction in carotid thickness is significantly associated with elevated levels of HDL-C, Apo C-III content of HDL (heparin supernate), and Apo A-I. Reduction in carotid thickness is significantly associated with reduced levels of LDL-C, Apo B, and total cholesterol (significant at 2 years only).
In multivariate stepwise regression of 2-year data combining drug and placebo groups, on-trial levels of Apo-B and HDL-C were independently associated with changes in wall thickness (R2=.36). Higher levels of HDL-C and lower levels of Apo-B were associated with reduced wall thickness. Stepwise regression using 4-year data yielded the same independent predictors (Apo B and HDL-C), with Apo C-Ill (whole serum) also entering (total R2=.41). In this model, higher levels of Apo C-III were associated with reduced intima-media thickness. Thus, risk factor correlations are compatible with those previously found in CLAS subjects for femoral10 and coronary atherosclerotic change.19 Discussion A pilot study of ultrasound imaging methodology included in CLAS indicates that colestipol-niacin therapy reduces intima-media thickness in the distal common carotid artery, evidence for possible reversal of early atherosclerotic involvement. Significant differences in change of intima-media thickness between drug and placebo subjects favoring treatment (P<.0001) appeared in a subset of 78 subjects at 2 years and persisted for 4 years ( Table 2 ). Equal evidence of benefit was found in a subset of 46 in which cervical angiogram views exactly matched carotid ultrasound images (Table 4) . For both subsets, we have demonstrated that risk factor levels at entry do not differ significantly from all remaining subjects randomized into CLAS. Furthermore, we have shown that on-trial risk factor levels do not differ in these subsets from all other Analysis uses drug and placebo subjects. *Correlation between (year 2 minus baseline) change in intimamedia thickness and year 2 on-trial measurements (weighted average of all on-trial measurements in first 2 years after randomization).
tCorrelation between (year 4 minus baseline) change in intimamedia thickness and year 4 on-trial measurements (weighted average of all on-trial measurements made over the entire 4-year study period).
CLAS subjects with the same treatment assignment. This is the first evidence from a controlled clinical trial of drug-induced improvement in carotid intima-media thickness. The subset of 46 subjects with matching cervical angiograms included only 22 and 24 per treatment group, but end-point analysis of the difference in group means, the simplest procedure for evaluation of a clinical trial, indicates significant therapy benefit. Our findings apply to carotid wall thickness before lesions intrude into the vessel. They do not apply to stenotic carotid disease as imaged by angiography or detected by Doppler ultrasound flow patterns. The distal common carotid artery lags behind the carotid bulb and internal carotid in formation of intrusive lesions but has a high prevalence of fatty streaks and fibrous plaques. This occurs in populations both at high and low risk of atherosclerosis. Our findings suggest that studies of intrusive lesions in other vascular areas can usefully be augmented with studies of preintrusive wall thickening in the distal common carotid.
On average, colestipol-niacin treatment and diet reduced LDL-C by 43% and increased HDL-C by 38%; diet alone in the placebo group reduced LDL-C by 5% and increased HDL-C by 3% (Table 3 ). Reduction of blood cholesterol level is known to induce generalized endothelium-dependent vessel relaxation,20,21 and this may have occurred to a greater extent in drug-treated subjects, but it cannot account for the difference in wall thickness that we have observed. In colestipol-niacin-treated subjects, reduction of intima-media thickness was not accompanied by an increase in carotid diameter. In fact, Tables 2 and 4 indicate nonsignificant changes in carotid diameter in a direction opposite to that expected if reduction in wall thickness were due to vessel wall stretching (ie, an expected increase in lumen diameter).
Poli and coworkers22 have shown that computer-assisted ultrasound measurements of carotid intima-media thickness are increased in hypercholesterolemic patients compared with normocholesterolemic control subjects. Hennerici et al,23 who also used a computer-assisted ultrasound procedure, reported reduction in the size of focal carotid lesions in seven heterozygous hyperlipoproteinemic patients treated with LDL pheresis. Our data indicate that carotid intima-media thickness can be reduced by aggressive blood cholesterol-lowering therapy when pretreatment LDL-C levels average 4.3 mmol/L (166 mg/dL), a range common in coronary disease patients. Our data also show that carotid intima-media thickening in the specific area that we have studied is significantly related at baseline (r=.34, P<.05) to average coronary stenosis. Thus, our findings support the growing use of ultrasound carotid imaging for study of coronary risk factors.24 Our findings are in accord with Salonen and Salonen,25 who reported that ultrasonically identifiable intima-media thickening in the common carotid artery is associated with a significant increase in risk for acute myocardial infarction.
Our 
Conclusions
We report a significant reduction in carotid intimamedia thickening after 2 and 4 years of treatment with colestipol-niacin plus diet therapy. On-trial increase in HDL-C and decrease in Apo-B levels were the best predictors of intima-media thickness reduction. The correlation of change in carotid thickness with other lipid, lipoprotein, and apolipoprotein levels is in accord with patterns previously observed in coronary and femoral arteries. Carotid intima-media thickness was significantly correlated with angiographic evidence of carotid and coronary atherosclerosis severity. Our findings suggest the feasibility of small-scale coronary risk factor trials using carotid intima-media thickness as an end point.
